Irritable bowel syndrome during the epidemic. Observations after 2 years of the COVID-19 pandemic Review article
Article Sidebar
Published:
Dec 31, 2021
Keywords:
irritable bowel syndrome, mebeverine, pandemic
Main Article Content
Abstract
Irritable bowel syndrome remains the most frequent cause of patients reporting to gastroenterology outpatient clinic. In the era of COVID-19 pandemic and anxiety, difficult direct contact to their physician, worse experiencing the isolation, expressed in patients’ non-complience to social distancing rules, leads to deterioration of symptoms, and consequently decreased life quality. The multitude of symptoms in patients with irritable bowel syndrome often requires therapy with more than one medication. In the diarrhoea predominant irritable bowel syndrome mebeverine remains useful for over 60 years.
Article Details
How to Cite
Janiak, M. (2021). Irritable bowel syndrome during the epidemic. Observations after 2 years of the COVID-19 pandemic. Medycyna Faktow (J EBM), 14(4(53), 364-368. https://doi.org/10.24292/01.MF.0421.X
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Mulak A, Smereka A, Paradowski L. Nowości i modyfikacje w Kryteriach Rzymskich IV. Gastroenterol Klin. 2016; 8(2): 52-61.
2. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Guidelines on the management of irritable bowel syndrome. Gastroenterology Rev. 2018; 13(4): 167-96.
3. Quek SXZ, Loo EXL, Demutska A et al. Impact of the coronavirus disease 2019 pandemic on irritable bowel syndrome. J Gastroenterol Hepatol. 2021; 36(8): 2187-97.
4. Oshima T, Siah KTH, Yoshimoto T et al. Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: A population- based survey. J Gastroenterol Hepatol. 2021; 36(7): 1820-7.
5. Drossman DA, Hasler WL. Rome IV – Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016; 150: 1257-61.
6. Chen B, Kim JJ, Zhang Y et al. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018; 53(7): 807-18.
7. Dlugosz A, Nowak P, D’Amato M et al. Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2015; 27(12): 1747-54.
8. Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007; 132(3): 913-20.
9. Halmos EP, Power VA, Shepherd SJ et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014; 146(1): 67-75.
10. Cho KH, Choi YK, Kang JH et al. Development of a novel combination tablet containing trimebutine maleate and mosaprid citrate for the treatment of functional dyspepsia. Intern J Pharmaceutics. 2010; 400: 145-52.
11. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010; 16(5): 547-53.
12. Lee KJ, Kim NY, Kwon JK et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011; 23: 1098-104.
13. Hou X, Chen S, Zhang Y et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34(11): 783-93.
2. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Guidelines on the management of irritable bowel syndrome. Gastroenterology Rev. 2018; 13(4): 167-96.
3. Quek SXZ, Loo EXL, Demutska A et al. Impact of the coronavirus disease 2019 pandemic on irritable bowel syndrome. J Gastroenterol Hepatol. 2021; 36(8): 2187-97.
4. Oshima T, Siah KTH, Yoshimoto T et al. Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: A population- based survey. J Gastroenterol Hepatol. 2021; 36(7): 1820-7.
5. Drossman DA, Hasler WL. Rome IV – Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016; 150: 1257-61.
6. Chen B, Kim JJ, Zhang Y et al. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018; 53(7): 807-18.
7. Dlugosz A, Nowak P, D’Amato M et al. Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2015; 27(12): 1747-54.
8. Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007; 132(3): 913-20.
9. Halmos EP, Power VA, Shepherd SJ et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014; 146(1): 67-75.
10. Cho KH, Choi YK, Kang JH et al. Development of a novel combination tablet containing trimebutine maleate and mosaprid citrate for the treatment of functional dyspepsia. Intern J Pharmaceutics. 2010; 400: 145-52.
11. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010; 16(5): 547-53.
12. Lee KJ, Kim NY, Kwon JK et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011; 23: 1098-104.
13. Hou X, Chen S, Zhang Y et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34(11): 783-93.